Amarin Corporation plc
Amarin Corporation plc
- Market cap
- $232.89M
Your view on AMRN
Overview
What the company does, where it operates, and who runs it.
About Amarin Corporation plc
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Aaron D. Berg
- Headquarters
- Grand Canal Docklands, Dublin, IE
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- Aaron D. Berg
- Headquarters
- Grand Canal Docklands, Dublin, IE
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates.
Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers.
It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999.
Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Amarin Corporation plc. Starting points for Amarin Corporation plc: EPS -$0.92, beta 0.79 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Amarin Corporation plc. Trailing twelve-month EPS for Amarin Corporation plc stands at -$0.92. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Hold
Targets, low to high
Analyst ratings
18 ratings- Strong Buy0
- Buy3
- Hold13
- Sell2
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −$0.08 | −$0.01 | −$1.13 | −$0.63 |
| Lowest estimate | −$0.09 | −$0.01 | −$1.15 | −$0.64 |
| Highest estimate | −$0.08 | −$0.01 | −$1.11 | −$0.62 |
| Number of analysts | 1 | 1 | 1 | 1 |
| A year ago | $0.011 | −$0.091 | −$36.001 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $49.90M | $43.23M | $183.35M | $189.05M |
| Lowest estimate | $47.61M | $42.71M | $180.35M | $175.87M |
| Highest estimate | $52.19M | $43.74M | $186.35M | $202.23M |
| Number of analysts | 1 | 1 | 1 | 1 |
| A year ago | $49.15M | $45.13M | $213.65M | — |
| Growth vs a year ago | +1.5% | −4.2% | −14.2% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Amarin Corporation plc. Amarin Corporation plc has reported as a listed company since 1993. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| ACIUAC Immune S.A. | Healthcare | Biotechnology | $213.7M | ||
| ALTAltimmune, Inc. | Healthcare | Biotechnology | $270.5M | ||
| ANROAlto Neuroscience, Inc. | Healthcare | Biotechnology | $1.0B | ||
| CLLSCellectis S.A. | Healthcare | Biotechnology | $103.8M | ||
| DBVTDBV Technologies S.A. | Healthcare | Biotechnology | $231.6M | ||
| ENGNenGene Holdings Inc. | Healthcare | Biotechnology | $124.0M | ||
| KRROKorro Bio, Inc. | Healthcare | Biotechnology | $170.7M | ||
| LRMRLarimar Therapeutics, Inc. | Healthcare | Biotechnology | $337.4M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| NONOFNovo Nordisk A/S | Healthcare | OTC | $168.6B | ||
| NVONovo Nordisk A/S | Healthcare | NYSE | $173.8B | ||
| NVSNovartis AG | Healthcare | NYSE | $293.1B | ||
| NVSEFNovartis AG | Healthcare | OTC | $316.8B | ||
| OGNOrganon & Co. | Healthcare | NYSE | $3.7B | ||
| OPHLFOno Pharmaceutical Co., Ltd. | Healthcare | OTC | $7.8B | ||
| OPHLYOno Pharmaceutical Co., Ltd. | Healthcare | OTC | $7.9B | ||
| ORINFOrion Oyj | Healthcare | OTC | $11.1B | ||
| ORINYOrion Oyj | Healthcare | OTC | $22.8B | ||
| OTSKFOtsuka Holdings Co., Ltd. | Healthcare | OTC | $35.4B | ||
| OTSKYOtsuka Holdings Co., Ltd. | Healthcare | OTC | $36.6B | ||
| PFEPfizer Inc. | Healthcare | NYSE | $159.9B | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| SPDWState Street SPDR Portfolio Developed World ex-US ETF | $41.0B in assets | 0.00% | |
| GWXState Street SPDR S&P International Small Cap ETF | $882M in assets | 0.01% | |
Largest holders first, then the funds most concentrated in AMRN.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Amarin Corporation plc, and how their positions are changing. At a $232.9M market value, institutional positions materially move Amarin Corporation plc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Amarin Corporation plc executives and directors. Shares of Amarin Corporation plc have traded between $7.00 and $20.90 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Amarin Corporation plc. Coverage tracks Amarin Corporation plc within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Amarin Corporation plc.